血浆DNA末端基序分析作为癌症、妊娠和移植中的片段组学标志物
该研究分析血浆DNA片段组学中的末端基序,发现肝细胞癌(HCC)患者血浆DNA末端基序多样性显著增加,4-mer末端基序模式偏好,且CCCA丰度明显低于无HCC者;其他癌种也见异常末端基序,同一组织来源的基序趋于聚类,提示其可作为液体活检标志物。
要点
- HCC患者血浆DNA末端基序多样性显著增加,4-mer基序模式偏好。
- HCC患者血浆DNA基序CCCA丰度明显低于无HCC者。
- 肝、胎盘及造血细胞来源的末端基序各自聚类,携带组织来源信息。
核心结论
- 血浆DNA末端基序谱可作为肿瘤、产前检测和移植监测的液体活检标志物。
研究设计与样本
- 研究分析血浆DNA片段组学中的末端基序,比较HCC患者与无HCC者,并观察其他癌种及不同组织来源的基序特征。
主要发现
- HCC患者血浆DNA末端基序多样性显著增加,呈4-mer末端基序偏好模式。
- HCC患者血浆DNA基序CCCA丰度明显低于无HCC者。
- 结直肠癌、肺癌、鼻咽癌和头颈鳞癌患者也可见异常末端基序。
- 肝、胎盘和造血细胞来源的血浆DNA末端基序谱通常各自聚类。
临床怎么用
- 血浆DNA末端基序谱有望用于肿瘤液体活检、无创产前检测和移植监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma DNA fragmentomics is an emerging area of research covering plasma DNA sizes, end points, and nucleosome footprints. In the present study, we found a significant increase in the diversity of plasma DNA end motifs in patients with hepatocellular carcinoma (HCC). Compared with patients without HCC, patients with HCC showed a preferential pattern of 4-mer end motifs. In particular, the abundance of plasma DNA motif CCCA was much lower in patients with HCC than in subjects without HCC. The aberrant end motifs were also observed in patients with other cancer types, including colorectal cancer, lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma. We further observed that the profile of plasma DNA end motifs originating from the same organ, such as the liver, placenta, and hematopoietic cells, generally clustered together. The profile of end motifs may therefore serve as a class of biomarkers for liquid biopsy in oncology, noninvasive prenatal testing, and transplantation monitoring. SIGNIFICANCE: Plasma DNA molecules originating from the liver, HCC and other cancers, placenta, and hematopoietic cells each harbor a set of characteristic plasma DNA end motifs. Such markers carry tissue-of-origin information and represent a new class of biomarkers in the nascent field of fragmentomics.This article is highlighted in the In This Issue feature, p. 627.
引用
- Jiang P, Sun K, Peng W, et al. Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discov. 2020. PMID: 32111602. doi:10.1158/2159-8290.CD-19-0622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。